Hodgkin lymphoma (HL) is one of the most curable pediatric and adult cancers, with long-
term survival rates now exceeding 90% after treatment with chemotherapy alone or …

Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative
disorders characterized by different clinical courses, varying from indolent to highly …

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide
recommendations for the management of adult patients with HL. The NCCN panel meets at …

Purpose The role of interim PET/CT in guiding therapeutic strategies in diffuse large B-cell
lymphoma (DLBCL) is debated, mainly because interpretation rules vary among centres …

The evolution of our understanding of the biology and management of the disease once
called Hodgkin disease, now called Hodgkin lymphoma (HL), has closely paralleled the …

Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma
(DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab …

High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the
standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B …

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative
disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas …

Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of
distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and …

This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the
management of classical HL. Current management of classical HL involves initial treatment …